Prognosis of Myelodysplastic Syndromes

Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 2079, 10.1182/blood.V89.6.2079

Haase, 2007, New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients, Blood, 110, 4385, 10.1182/blood-2007-03-082404

Malcovati, 2007, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes, J Clin Oncol, 25, 3503, 10.1200/JCO.2006.08.5696

Malcovati, 2005, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making, J Clin Oncol, 23, 7594, 10.1200/JCO.2005.01.7038

Sanz, 2008, Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome, Blood, 112, 640, 10.1182/blood.V112.11.640.640

Vardiman, 2009, The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262

Harris, 1999, The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues, Ann Oncol, 1419

Garcia-Manero, 2008, A prognostic score for patients with lower risk myelodysplastic syndrome, Leukemia, 22, 538, 10.1038/sj.leu.2405070

Dayyani, 2010, Cause of death in patients with lower-risk myelodysplastic syndrome, Cancer, 116, 2174, 10.1002/cncr.24984

Kantarjian, 2008, Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System, Cancer, 113, 1351, 10.1002/cncr.23697

Szpurka, 2006, Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation, Blood, 108, 2173, 10.1182/blood-2006-02-005751

Atallah, 2008, Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis, Leukemia, 22, 1295, 10.1038/sj.leu.2405054

Della Porta, 2009, Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes, J Clin Oncol, 27, 754, 10.1200/JCO.2008.18.2246

Thiele, 2005, European consensus on grading bone marrow fibrosis and assessment of cellularity, Haematologica, 90, 1128

Wijermans, 2008, Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML), Leuk Res, 32, 587, 10.1016/j.leukres.2007.08.004

Aribi, 2007, Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia, Cancer, 109, 713, 10.1002/cncr.22457

Onida, 2002, Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients, Blood, 99, 840, 10.1182/blood.V99.3.840

Ricci, RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant, Clin Cancer Res, 16, 2246, 10.1158/1078-0432.CCR-09-2112

Makishima, 2009, Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies, J Clin Oncol, 27, 6109, 10.1200/JCO.2009.23.7503

Kim, 2009, A prognostic model of therapy-related myelodysplastic syndrome [abstract], Blood, 114, 3796, 10.1182/blood.V114.22.3796.3796

Young, 2006, Current concepts in the pathophysiology and treatment of aplastic anemia, Blood, 108, 2509, 10.1182/blood-2006-03-010777

Saunthararajah, 2003, A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome, Blood, 102, 3025, 10.1182/blood-2002-11-3325

Tong, 2009, Prognostic factors and survival in patients with hypocellular myelodysplastic syndrome: development of a disease specific prognostic score, Blood, 114, 3819, 10.1182/blood.V114.22.3819.3819

Huang, 2008, Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies, Leukemia, 22, 544, 10.1038/sj.leu.2405076

Rollison, 2008, Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs, Blood, 112, 45, 10.1182/blood-2008-01-134858

Wang, 2009, Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes, Leuk Res, 33, 1594, 10.1016/j.leukres.2009.02.005

Naqvi, 2009, Comorbidities and myelodysplatic syndromes, Blood, 114, 2789, 10.1182/blood.V114.22.2789.2789

Read, 2004, Differential prognostic impact of comorbidity, J Clin Oncol, 22, 3099, 10.1200/JCO.2004.08.040

List, 2006, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion, N Engl J Med, 355, 1456, 10.1056/NEJMoa061292

Kantarjian, 2009, The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?, Cancer, 115, 5202, 10.1002/cncr.24575

Maciejewski, 2008, Whole genome scanning as a cytogenetic tool in hematologic malignancies, Blood, 112, 965, 10.1182/blood-2008-02-130435

Gondek, 2008, Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML, Blood, 111, 1534, 10.1182/blood-2007-05-092304

Mohamedali, 2007, Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes, Blood, 110, 3365, 10.1182/blood-2007-03-079673

Heinrichs, 2009, Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics, Leukemia, 23, 1605, 10.1038/leu.2009.82

O'Keefe, Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies, Blood, 115, 2731, 10.1182/blood-2009-10-201848

Bernasconi, 2008, Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions–a review, Br J Haematol, 142, 695, 10.1111/j.1365-2141.2008.07245.x

Sanada, 2009, Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms, Nature, 460, 904, 10.1038/nature08240

Dunbar, 2008, 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies, Cancer Res, 68, 10349, 10.1158/0008-5472.CAN-08-2754

Fisher, 2006, Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the Asx-like gene family, Gene, 369, 109, 10.1016/j.gene.2005.10.033

Gelsi-Boyer, 2009, Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br J Haematol, 145, 788, 10.1111/j.1365-2141.2009.07697.x

Boultwood, 2010, Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia, Leukemia, 24, 1062, 10.1038/leu.2010.20

Delhommeau, 2009, Mutation in TET2 in myeloid cancers, N Engl J Med, 360, 2289, 10.1056/NEJMoa0810069

Abdel-Wahab, 2009, Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies, Blood, 114, 144, 10.1182/blood-2009-03-210039

Jankowska, 2009, Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms, Blood, 113, 6403, 10.1182/blood-2009-02-205690

Mohamedali, 2009, Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome, J Clin Oncol, 27, 4002, 10.1200/JCO.2009.22.6985

Langemeijer, 2009, Acquired mutations in TET2 are common in myelodysplastic syndromes, Nat Genet, 41, 838, 10.1038/ng.391

Kosmider, 2009, TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs), Blood, 114, 3285, 10.1182/blood-2009-04-215814

Kosmider, 2009, TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia, Haematologica, 94, 1676, 10.3324/haematol.2009.011205

Tahiliani, 2009, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1, Science, 324, 930, 10.1126/science.1170116

Garcia-Manero, 2007, Modifying the epigenome as a therapeutic strategy in myelodysplasia, Hematology Am Soc Hematol Educ Program, 2007, 405, 10.1182/asheducation-2007.1.405

Shen, 2010, DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes, J Clin Oncol, 28, 605, 10.1200/JCO.2009.23.4781

Jiang, 2009, Aberrant DNA methylation is a dominant mechanism in MDS progression to AML, Blood, 113, 1315, 10.1182/blood-2008-06-163246

Figueroa, 2009, MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation, Blood, 114, 3448, 10.1182/blood-2009-01-200519

Fenaux, 2009, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol, 10, 223, 10.1016/S1470-2045(09)70003-8

Kantarjian, 2006, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study, Cancer, 106, 1794, 10.1002/cncr.21792

Ebert, 2008, Identification of RPS14 as a 5q- syndrome gene by RNA interference screen, Nature, 451, 335, 10.1038/nature06494

Starczynowski, 2010, Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype, Nat Med, 16, 49, 10.1038/nm.2054

Pellagatti, 2007, Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients, Proc Natl Acad Sci U S A, 104, 11406, 10.1073/pnas.0610477104

Ebert, 2008, An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome, PLoS Med, 5, e35, 10.1371/journal.pmed.0050035

Wei, 2009, A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide, Proc Natl Acad Sci U S A, 106, 12974, 10.1073/pnas.0811267106

Jadersten, 2006, Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need [abstract], Blood, 108, 521, 10.1182/blood.V108.11.521.521

Lim, 2007, Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin, Leukemia, 21, 1436, 10.1038/sj.leu.2404747

Zou, 2009, Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome, Leukemia, 23, 1288, 10.1038/leu.2009.14

Soriano, 2007, Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome, Blood, 110, 2302, 10.1182/blood-2007-03-078576

Garcia-Manero, 2006, Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia, Blood, 108, 3271, 10.1182/blood-2006-03-009142

Blum, 2010, Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine, Proc Natl Acad Sci U S A, 107, 7473, 10.1073/pnas.1002650107